# SUPPLY of LUTATHERA® (lutetium Lu 177 dotatate) and PLUVICTO™ (lutetium Lu 177 vipivotide tetraxetan)

Canonical: https://abierto.us/opportunities/12481254

- Solicitation number: 12481254
- Notice type: Award notice
- Status: Awarded to Novartis Pharmaceuticals Corporation for $480,119.64
- Department: Department of Defense
- Agency: Defense Health Agency (Dha)
- Contracting office: Defense Health Agency (HT0014)
- Place of performance: Bethesda, Maryland
- County: Montgomery County (FIPS 24031). https://abierto.us/counties/montgomery-county-md-24031
- City: Bethesda. https://abierto.us/cities/bethesda-md-2407125
- First posted: October 8, 2026
- Last posted: October 8, 2026
- SAM.gov: https://sam.gov/workspace/contract/opp/b282dc9e8acc4a928ab3a5823a5dd0f3/view

## Description

Clinical Utility: It is used for targeted radioligand therapy for specific types of prostate cancer within the Nuclear Medicine Division of the Department of Radiology at WRNMMC. Novartis Pharmaceuticals Corporation is the sole source for Pluvicto. Therefore, the recommended course of action is to award a contract directly to Novartis. This approach is deemed to be in the government's best interest to ensure the seamless delivery of these critical supplies and maintain continuity of patient care at WRNMMC. The acquisition will be treated as a sole-source procurement.

## Publications

- October 8, 2026: Award notice. Notice b282dc9e8acc4a928ab3a5823a5dd0f3. https://sam.gov/workspace/contract/opp/b282dc9e8acc4a928ab3a5823a5dd0f3/view

---
Source: SAM.gov Contract Opportunities bulk extract. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/12481254.